ABLYNX ANNOUNCES AN EXTENSION OF ITS GLOBAL STRATEGIC NANOBODY ALLIANCE WITH BOEHRINGER INGELHEIM

(Thomson Reuters ONE) -


GHENT, Belgium, 20 March 2012 - Ablynx [Euronext Brussels: ABLX] today announced
a two-year extension of the initial five-year research funding by Boehringer
Ingelheim of their global strategic alliance to discover, develop and
commercialise up to 10 different Nanobody(®) therapeutics. The extension which
will run until September 2014, will allow all the existing ten Nanobody
programmes to advance to a stage where Boehringer Ingelheim can potentially
progress each programme into development. Ablynx will receive a total of ?6.6
million in additional research funding from Boehringer Ingelheim, some of which
will be in advance. This payment is in return for work carried out by Ablynx's
specialist Nanobody scientists. Ablynx has already received over ?58 million
from payments under the Strategic Alliance since it was signed in 2007.

In September 2007, Ablynx and Boehringer Ingelheim entered into a Strategic
Alliance on the discovery, development and commercialisation of Nanobody
therapeutics across a range of diseases, including oncology, immunology, and
respiratory diseases. The agreement allows for potential milestone payments of
up to ?125 million plus royalties to Ablynx for each Nanobody which reaches
market. Boehringer Ingelheim is exclusively responsible for the development,
manufacturing and commercialisation of any products resulting from the
collaboration. Ablynx retains certain co-promotion rights in Europe.

Dr Edwin Moses, CEO and Chairman of Ablynx, said:

"We are delighted to extend the current Strategic Alliance. As a result of this
very successful collaboration, there are now two Nanobody programmes already in
pre-clinical development and seven Nanobodies at various stages in discovery
across multiple disease areas. In addition, as part of a separate collaboration

with Boehringer Ingelheim, there is a Nanobody relevant in Alzheimer's disease
also at the pre-clinical development stage. We are very pleased to have eleven
Nanobody programmes potentially able to make an important contribution to
Boehringer Ingelheim's R&D pipeline."




About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious and life-threatening human diseases,
including inflammation, haematology, oncology and pulmonary disease. Today, the
Company has over 25 programmes in the pipeline and seven Nanobodies at clinical
development stage. Ablynx has ongoing research collaborations and significant
partnerships with major pharmaceutical companies, including Boehringer
Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent,
Belgium. More information can be found on www.ablynx.com.


For more information, please contact

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses(at)ablynx.com

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch(at)ablynx.com

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t:   +44 207 920 2330
e:  ablynx(at)mcomgroup.com




Complete version of the press release:
http://hugin.info/137912/R/1595865/502617.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE
[HUG#1595865]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 20.03.2012 - 17:40 Uhr
Sprache: Deutsch
News-ID 126751
Anzahl Zeichen: 4392

contact information:
Town:

Ghent

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 154 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ABLYNX ANNOUNCES AN EXTENSION OF ITS GLOBAL STRATEGIC NANOBODY ALLIANCE WITH BOEHRINGER INGELHEIM"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx